Results 21 to 30 of about 142,420 (373)

Cholangiocarcinoma 2020: the next horizon in mechanisms and management

Nature reviews: Gastroenterology & hepatology, 2020
Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant tumours that can arise at any point of the biliary tree. Their incidence is increasing globally, currently accounting for ~15% of all primary liver cancers and ~3% of ...
J. Banales, J. Marin, A. Lamarca, P. Rodrigues, Shahid A. Khan, L. Roberts, V. Cardinale, G. Carpino, J. Andersen, C. Braconi, D. Calvisi, M. Perugorria, L. Fabris, L. Boulter, R. Macías, E. Gaudio, D. Alvaro, S. Gradilone, M. Strazzabosco, M. Marzioni, C. Coulouarn, L. Fouassier, C. Raggi, P. Invernizzi, J. Mertens, A. Moncsek, Sumera Rizvi, J. Heimbach, B. Koerkamp, J. Bruix, A. Forner, J. Bridgewater, J. Valle, G. Gores   +33 more
semanticscholar   +1 more source

Establishment of a Potential Serum Biomarker Panel for the Diagnosis and Prognosis of Cholangiocarcinoma Using Decision Tree Algorithms

Diagnostics, 2021
Potential biomarkers which include S100 calcium binding protein A9 (S100A9), mucin 5AC (MUC5AC), transforming growth factor β1 (TGF-β1), and angiopoietin-2 have previously been shown to be effective for cholangiocarcinoma (CCA) diagnosis.
Phongsaran Kimawaha, Apinya Jusakul, Prem Junsawang, Raynoo Thanan, Attapol Titapun, Narong Khuntikeo, Anchalee Techasen   +6 more
doaj   +1 more source

Cold-atmospheric plasma induces tumor cell death in preclinical in vivo and in vitro models of human cholangiocarcinoma [PDF]

Cancers, 12, 1280, 2020, 2020
Through the last decade, cold atmospheric plasma (CAP) has emerged as an innovative therapeutic option for cancer treatment. Recently, we have set up a potentially safe atmospheric pressure plasma jet device that displays antitumoral properties in a preclinical model of cholangiocarcinoma (CCA), a rare and very aggressive cancer emerging from the ...
arxiv   +1 more source

EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma.

Cancer Discovery, 2022
FGFR inhibitors are approved for the treatment of advanced cholangiocarcinoma harboring FGFR2 fusions. However, the response rate is moderate, and resistance emerges rapidly due to acquired secondary FGFR2 mutations or due to other less-defined ...
Qibiao Wu, Yuanli Zhen, Lei Shi, P. Vu, Patricia Greninger, Ramzi Adil, J. Merritt, Regina K. Egan, Meng‐Ju Wu, Xunqin Yin, Cristina R. Ferrone, V. Deshpande, I. Baiev, C. Pinto, D. McLoughlin, C. Walmsley, James R. Stone, J. Gordan, A. Zhu, D. Juric, L. Goyal, C. Benes, N. Bardeesy   +22 more
semanticscholar   +1 more source

ESMO Scale for Clinical Actionability of Molecular Targets driving targeted treatment in patients with cholangiocarcinoma.

Clinical Cancer Research, 2022
Purpose: Treatment options for advanced cholangiocarcinoma are limited and prognosis is poor. Cholangiocarcinomas are highly heterogeneous at the molecular level, with divergent patterns between intrahepatic and extrahepatic forms, intrahepatic being ...
H. Verdaguer, T. Saurí, Daniel Alejandro Acosta, Magdalena Guardiola, Alexandre Sierra, Jorge Hernando, P. Nuciforo, J. Miquel, Cristina Molero, Sandra Peiró, Q. Serra-Camprubí, G. Villacampa, S. Aguilar, A. Vivancos, J. Tabernero, R. Dienstmann, T. Macarulla   +16 more
semanticscholar   +1 more source

Metabolic Phenotyping Predicts Gemcitabine and Cisplatin Chemosensitivity in Patients With Cholangiocarcinoma

Frontiers in Public Health, 2022
Gemcitabine and cisplatin serve as appropriate treatments for patients with cholangiocarcinoma (CCA). Our previous study using histoculture drug response assay (HDRA), demonstrated individual response patterns to gemcitabine and cisplatin.
Manida Suksawat, Manida Suksawat, Manida Suksawat, Jutarop Phetcharaburanin, Jutarop Phetcharaburanin, Jutarop Phetcharaburanin, Jutarop Phetcharaburanin, Poramate Klanrit, Poramate Klanrit, Poramate Klanrit, Nisana Namwat, Nisana Namwat, Nisana Namwat, Narong Khuntikeo, Narong Khuntikeo, Narong Khuntikeo, Attapon Titapun, Attapon Titapun, Attapon Titapun, Apiwat Jarearnrat, Apiwat Jarearnrat, Apiwat Jarearnrat, Vanlakhone Vilayhong, Vanlakhone Vilayhong, Vanlakhone Vilayhong, Prakasit Sa-ngiamwibool, Prakasit Sa-ngiamwibool, Prakasit Sa-ngiamwibool, Anchalee Techasen, Anchalee Techasen, Anchalee Techasen, Arporn Wangwiwatsin, Arporn Wangwiwatsin, Arporn Wangwiwatsin, Arporn Wangwiwatsin, Panupong Mahalapbutr, Panupong Mahalapbutr, Jia V. Li, Watcharin Loilome, Watcharin Loilome, Watcharin Loilome, Watcharin Loilome   +41 more
doaj   +1 more source

Intrahepatic cholangiocarcinoma: review and update [PDF]

, 2018
Cholangiocarcinoma (CCA) is a heterogeneous group of malignancies that could develop at any level from the biliary tree. CCA is currently classified into intrahepatic (iCCA), perihilar and distal on the basis of its anatomical location.
Alvaro, Domenico, Bragazzi, Maria Consiglia, Cardinale, Vincenzo, Carpino, Guido, Di Matteo, Sabina, Gaudio, Eugenio, Nevi, Lorenzo, Overi, Diletta   +7 more
core   +1 more source

Modulation of STAT3 signaling, cell redox defenses and cell cycle checkpoints by β-caryophyllene in cholangiocarcinoma cells: possible mechanisms accounting for doxorubicin chemosensitization and chemoprevention [PDF]

, 2020
Cholangiocarcinoma (CCA) is an aggressive group of biliary tract cancers, characterized by late diagnosis, low effective chemotherapies, multidrug resistance, and poor outcomes.
Di Giacomo, Silvia, Di Sotto, Antonella, Eufemi, Margherita, Gulli, Marco, Macone, Alberto, Mammola, Caterina Loredana, Mancinelli, Romina, Mazzanti, Gabriela, Rubini, Elisabetta   +8 more
core   +1 more source

Cholangiocarcinoma

Neoplasms of the Biliary Tract, 2020
Cholangiocarcinomas are tumors that arise from the biliary tract, a part of the digestive system. Although rare, these types of tumors have shown a steady increasing in prevalence and now account for 3% of all gastrointestinal (GI) cancers. These cancers
Jae Hoon Lim, Kee-Taek Jang, Jung Hoon Kim   +2 more
semanticscholar   +1 more source

Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma

Hepatology, 2021
Genetic alterations in intrahepatic cholangiocarcinoma (iCCA) are increasingly well characterized, but their impact on outcome and prognosis remains unknown.
T. Boerner, E. Drill, L. Pak, Bastien Nguyen, C. Sigel, A. Doussot, P. Shin, D. Goldman, M. Gonen, P. Allen, V. Balachandran, A. Cercek, J. Harding, D. Solit, N. Schultz, Ritika Kundra, H. Walch, M. D'Angelica, R. DeMatteo, J. Drebin, N. Kemeny, T. Kingham, Amber L. Simpson, J. Hechtman, E. Vakiani, M. Lowery, J. Ijzermans, S. Buettner, B. Koerkamp, M. Doukas, R. Chandwani, W. Jarnagin   +31 more
semanticscholar   +1 more source